Loading company
SAB Biotherapeutics, Inc.
SABS · Nasdaq · ·
$3.23+0.5%Sep 29 close
- 1M
- -14.8%
- 6M
- -14.6%
- 1Y
- +60.7%
- 5Y
- -96.8%
SABS · Nasdaq · ·
$3.23+0.5%Sep 29 close
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $114.7K | $305K | -62.40% |
| Profit | -$22.5M | -$10.1M | -122.37% |
| Profit per share | -$0.28 | -$1.09 | +74.31% |
| Free Cash Flow | -$11.4M | -$7.8M | -47.06% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
SAB Biotherapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from SAB Biotherapeutics, Inc.’s Item 2.02 8-K filed March 29, 2024; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.